Welcome to our dedicated page for Aptose Bioscienc SEC filings (Ticker: APTOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aptose Biosciences Inc. (APTOF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Canadian issuer reporting to the U.S. Securities and Exchange Commission. Aptose files current reports on Form 8-K under Commission File Number 001-32001, alongside its Canadian securities filings. These documents are central for investors who want to understand the company’s clinical-stage oncology business, financial condition, and pending corporate transactions.
For Aptose, Form 8-K filings are particularly important. Recent 8-Ks include Regulation FD disclosures that furnish press releases about tuspetinib (TUS) clinical data from the TUSCANY Phase 1/2 trial, including safety, complete remission (CR/CRh) rates, and minimal residual disease (MRD) findings in acute myeloid leukemia (AML). Other 8-Ks report quarterly financial results, detailing research and development expenses by program, general and administrative costs, cash balances, and the company’s reliance on loan facilities from Hanmi Pharmaceutical Co. Ltd. to fund operations.
Another critical category of filings relates to material definitive agreements and corporate transactions. Aptose has filed an 8-K describing its definitive arrangement agreement with Hanmi and HS North America Ltd., under which a Hanmi subsidiary will acquire all Aptose common shares not already owned or controlled by Hanmi or its affiliates, subject to shareholder and court approvals. That filing outlines the transaction structure, consideration for minority shareholders, required approvals, and the expectation that, after completion, Aptose will no longer be subject to certain reporting requirements and its shares will be delisted from stock exchanges including the TSX.
Through Stock Titan, investors can review these filings and use AI-powered summaries to interpret key sections, such as risk factor discussions, forward-looking statements, and the implications of financing and transaction agreements. The platform also tracks new 8-Ks in real time, helping users monitor Aptose’s ongoing clinical disclosures, financial updates, and progress toward the proposed acquisition.
Aptose Biosciences Inc., a clinical-stage oncology biotech focused on hematologic cancers, has agreed to be acquired by Hanmi Pharmaceutical via a Canadian plan of arrangement. Hanmi’s subsidiary will purchase all Aptose common shares it does not already control for C$2.41 in cash per share, with all options, RSUs and warrants cancelled at closing and the shares delisted from the Toronto Stock Exchange.
Shareholders approved the transaction on March 31, 2026, and the outside closing date was extended to June 30, 2026, but completion still depends on regulatory and court approvals and the absence of legal restraints. The company warns that if the deal fails, its business, financial results and share price could be adversely affected and it may need to consider insolvency.
Aptose’s lead asset, tuspetinib, is an oral kinase inhibitor being developed mainly in frontline triple therapy with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia. Across early Phase 1/2 studies, the TUS+VEN+AZA triplet has shown high composite complete remission and minimal residual disease–negative response rates in genetically diverse, often hard‑to‑treat AML patients, with a consistently favorable safety profile.
Aptose Biosciences Inc. reported that shareholders approved a plan of arrangement under which a Hanmi Pharmaceutical subsidiary will acquire all Aptose common shares not already owned by Hanmi for C$2.41 in cash per share, a 28% premium to the 30‑day VWAP of C$1.88. The company also received a final court order from the Court of King’s Bench of Alberta approving the transaction, with closing expected by the end of April 2026, subject to remaining conditions.
Clinically, the TUSCANY study of the TUS+VEN+AZA triplet in newly diagnosed AML showed high-quality responses, with CR/CRh rates of 90% across 40–120 mg TUS doses, 100% at 80 mg and 120 mg, and 78% MRD‑negative remissions among responders, alongside a favorable safety profile.
Financially, for 2025 Aptose recorded a net loss of $25.5 million, similar to 2024, on reduced research and development expenses of $11.3 million versus $15.1 million a year earlier. Year-end 2025 cash and equivalents were $4.1 million, with working capital of $(2.9) million and shareholders’ deficit of $(27.2) million, and operations have been funded by more than US$41 million of Hanmi debt facilities.
Aptose Biosciences Inc. reported the results of a special shareholder meeting held on March 31, 2026. Shareholders approved a continuance of the corporation from the Canada Business Corporations Act to the Business Corporations Act (Alberta), and also approved a plan of arrangement with Hanmi-related entities.
Under the approved arrangement, HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd., will acquire all Aptose common shares not already owned or controlled by the Hanmi entities or their affiliates. The continuance resolution received roughly 92.42% of votes cast in favor, while the arrangement resolution received about 84.87% support, indicating strong shareholder backing for both the corporate law change and the proposed acquisition structure.
Aptose Biosciences Inc. reported an amendment to the employment agreement of its Chairman, President and Chief Executive Officer, Dr. William Rice. The First Amendment to the Second Amended and Restated Employment Agreement, effective March 12, 2026, clarifies that no deferred compensation plan was ever created, no deferred compensation was earned, and no deferred compensation benefits are owed to Dr. Rice. It also confirms that Dr. Rice is solely responsible for any potential individual taxes, penalties and interest on all benefits paid or payable under his current and prior agreements. The full text of the First Amendment is included as an exhibit.
Aptose Biosciences Inc. reported that proxy advisor Glass Lewis has recommended shareholders vote “FOR” its proposed plan of arrangement with Hanmi Pharmaceutical. Under this arrangement, Hanmi and its subsidiary would acquire all Aptose common shares not already owned by them. Shareholders are being asked to approve both the Arrangement and a continuance of Aptose from the CBCA to the ABCA at a reconvened virtual special meeting on March 31, 2026. The proxy voting deadline is 11:00 a.m. (Eastern time) on March 27, 2026. Aptose’s Special Transaction Committee and Board unanimously recommend voting FOR the Continuance and the Arrangement, which remain subject to customary conditions, including Court approval and TSX approval.
Aptose Biosciences Inc. announced that proxy advisory firm ISS has recommended shareholders vote “FOR” a special resolution approving the previously disclosed plan of arrangement under which Hanmi Pharmaceutical and its subsidiary will acquire all Aptose common shares they do not already own.
Under the proposed transaction, Aptose shareholders other than the Hanmi buyers and their affiliates would receive C$2.41 in cash per share, described as a 28% premium to Aptose’s 30-day VWAP of C$1.88 on the TSX. ISS also recommended approval of a corporate continuance from the CBCA to the ABCA, which it viewed as having largely similar shareholder rights.
A special meeting to vote on the arrangement and continuance has been reconvened for March 31, 2026, with a proxy voting deadline of 11:00 a.m. Eastern time on March 27, 2026. Completion of the transaction remains subject to shareholder approval, court approval, TSX approval and other customary closing conditions.
Aptose Biosciences Inc. detailed changes to its planned acquisition by a subsidiary of Hanmi Pharmaceutical and an expanded funding arrangement to support its lead drug Tuspetinib. An amended and restated arrangement agreement keeps in place the plan for Hanmi’s HS North America Ltd. to acquire all Aptose common shares it does not already own by way of a statutory plan of arrangement under Alberta law, and reconvenes the special shareholder meeting for March 31, 2026. Aptose’s board unanimously recommends that shareholders vote in favor of the continuance and the Arrangement.
The company also entered into a US$11.1 million second amended and restated facility agreement with Hanmi, providing multiple interest-bearing advances at 6% per annum to fund business and clinical expenses tied to Tuspetinib in acute myeloid leukemia. Prior Hanmi facilities were treated as related-party transactions under Canadian rules, with Aptose’s board unanimously concluding, under a financial hardship exemption, that these financings improve the company’s financial position and are reasonable in the circumstances.
Aptose Biosciences Inc. is asking shareholders to approve a continuance to the ABCA and a statutory plan of arrangement under which HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd., will acquire all outstanding common shares (other than Parent-held shares) for C$2.41 per Share.
The Board and its independent Transaction Committee unanimously recommend that shareholders vote FOR both the Continuance and Arrangement Resolutions. Locust Walk delivered a Formal Valuation estimating fair market value at C$1.00 to C$5.08 per Share (as of November 18, 2025). The special meeting is virtual on March 31, 2026; the Record Date for voting is February 24, 2026. As of the Record Date, 2,552,429 Shares were outstanding.
Aptose Biosciences Inc. is asking shareholders to approve its acquisition by HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical, via a court-approved plan of arrangement. Public shareholders would receive C$2.41 in cash per share, with Hanmi’s existing holdings excluded from the payout.
The deal requires a continuance of Aptose from the CBCA to the ABCA and special resolutions approving both the continuance and the arrangement, including a two‑thirds majority and a separate majority of disinterested shares under MI 61‑101. A special committee obtained a formal valuation from Locust Walk of C$1.00–C$5.08 per share and a fairness opinion supporting the cash consideration.
If completed, Aptose will become an indirect wholly owned subsidiary of Hanmi, its shares will be delisted from the TSX and OTC Markets, and it will cease to be a reporting issuer in Canada and under the U.S. Exchange Act. Registered shareholders have dissent rights to seek fair value, subject to strict procedures and deadlines, while failure to close in certain circumstances could lead to court‑supervised CCAA proceedings.